Evidence map›Paper›PMID 9234795›Full record

ArticleInfection and immunity1997

Sensitization of human umbilical vein endothelial cells to Shiga toxin: involvement of protein kinase C and NF-kappaB.

C B Louise, M C Tran, T G Obrig

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Shiga toxin pathogenesis: kidney complications and renal failure.Current topics in microbiology and immunology · 2012
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Shiga Toxin-Producing Escherichia coli.Current infectious disease reports · 2000
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

C B LouiseDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, New York 14642, USA.
M C Tran
T G Obrig
University of Rochester · US

Funding

SHIGA TOXIN MODE OF ACTION IN BACTERIAL DISEASESR01AI024431 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI OBRIG, TOM G · 1989 to 2007
$2.9M
SHIGA TOXIN MODE OF ACTION IN BACTERIAL DISEASESR22AI024431 · NIAID · ALBANY MEDICAL COLLEGE · PI OBRIG, TOM G · 1987 to 1989
–
NIAID NIH HHS AI24431
6 · The paper itself

Abstract

Infection of humans with Shiga toxin-producing Escherichia coli O157:H7 and Shigella dysenteriae 1 is strongly associated with vascular endothelial cell damage and the development of hemolytic-uremic syndrome. The cytotoxic effect of Shiga toxins on vascular endothelial cells in vitro is enhanced by prior exposure to bacterial lipopolysaccharide (LPS) or either of the host cytokines tumor necrosis factor alpha (TNF) and interleukin-1beta (IL-1). The purpose of this study was to examine individual signal transduction components involved in the sensitization of human umbilical vein endothelial cells (HUVEC) to Shiga toxin 1. The results demonstrate that class I and II protein kinase C (PKC) isozymes are required for sensitization of HUVEC to Shiga toxin by phorbol myristate acetate (PMA) or LPS but not by TNF or IL-1. Thus, the specific competitive inhibitor of class I/II PKC, 1-O-hexadecyl-2-O-methyl-rac-glycerol (AMG), prevented only the action of PMA and LPS on HUVEC. Additional data obtained with ATP binding site inhibitors which affect all PKCs (i.e., classes I, II, and III) suggest that TNF may utilize class III PKC isozymes in the Shiga toxin sensitization of HUVEC. Transcriptional activator NF-kappaB did not appear to be involved in the sensitization of HUVEC to Shiga toxin by LPS, TNF, IL-1, or PMA. Thus, the specific serine protease inhibitor L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK) did not inhibit the sensitization of HUVEC to Shiga toxin by LPS, TNF, IL-1, or PMA despite its ability to inhibit NF-kappaB activation and the induction of the NF-kappaB-dependent tissue factor gene by these agents. Finally, all-trans retinoic acid partially inhibited the sensitization of HUVEC to Shiga toxin, by unknown mechanisms which also appeared to be independent of NF-kappaB activation. These results indicate that PKC plays a role in the sensitization of HUVEC to Shiga toxin in response to some, but not all, sensitizing agents. In contrast, NF-kappaB activation appears not to be involved in the sensitization of HUVEC to Shiga toxin by LPS, TNF, IL-1, or PMA.

Indexed as

Bacterial ToxinsEndothelium, VascularHumansInterleukin-1LipopolysaccharidesNF-kappa BProtein Kinase CShiga ToxinsTetradecanoylphorbol AcetateTosylphenylalanyl Chloromethyl KetoneTretinoinTumor Necrosis Factor-alphaUmbilical VeinsBacterial ToxinsInterleukin-1LipopolysaccharidesNF-kappa BProtein Kinase CShiga ToxinsTetradecanoylphorbol AcetateTosylphenylalanyl Chloromethyl KetoneTretinoinTumor Necrosis Factor-alpha

Identifiers

PMID9234795
PMCPMC175472
OpenAlexW1820099508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.